Corrigendum: Inhibition of EZH2 expression is associated with the proliferation, apoptosis and migration of SW620 colorectal cancer cells in vitro [Experimental Biology and Medicine, (2014), DOI 10.1177/1535370214542215];Inhibition of EZH2 expression is associated with the proliferation, apoptosis, and migration of SW620 colorectal cancer cells in vitro

Experimental Biology and Medicine

Volumn 240, Issue 4, 2015, Pages 458-466

  He, Song Bing ^a,b   Zhou, Hao ^b   Zhou, Jian ^b   Zhou, Guo Qiang ^c   Han, Tuo ^b   Wan, Dai Wei ^d   Gu, Wen ^b   Gao, Lin ^b   Zhang, Yi ^b   Xue, Xiao Feng ^b   Zhang, Li Feng ^b   Fei, Min ^b   Hu, Shui Qing ^a   Yang, Xiao Dong ^e   Zhu, Xin Guo ^b   Wang, Liang ^b   Li, De Chun ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c the Second People s Hospital of Changshu   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^e THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

apoptosis; colorectal cancer; EZH2; migration; proliferation; small interfering RNA

Indexed keywords

SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MTT ASSAY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CELL MOTION; COLORECTAL NEOPLASMS; DRUG EFFECTS; FEMALE; IN VITRO STUDY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE;

ADENOCARCINOMA; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IN VITRO TECHNIQUES; MALE; MIDDLE AGED; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84927798981     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370214542215     Document Type: Erratum

References (43)

1. Siegel R,Naishadham D,Jemal A.Cancer statistics, 2013.CA Cancer J Clin. 2013;63:11-30
2. Brenner H,Kloor M,Pox CP.Colorectal cancer.Lancet. 2013;S0140–6736:61649-9
3. Weinstock B,Ward SC,Harpaz N,Warner RR,Itzkowitz S,Kim MK.Clinical and prognostic features of rectal neuroendocrine tumors.Neuroendocrinology. 2013;98:180-7
4. Wan D, Gu W, Xu G, Shen C, Ding D, Shen S, Wang S, Gong X, He S, Zhi Q. Effects of common polymorphisms rs2910164 in miR-146a and rs11614913 in miR-196a2 on susceptibility to colorectal cancer: A systematic review meta-analysis. Clin Transl Oncol. Epub ahead of print 8 January 2014, DOI:10.1007/s12094-013-1150-x.
5. Dawson MA,Kouzarides T.Cancer epigenetics: From mechanism to therapy.Cell. 2012;150:12-27
6. He S,Xie F,Liu Y,Tong Q,Mochizuki K,Lapinski PE,Mani RS,Reddy P,Mochizuki I,Chinnaiyan AM,Mineishi S,King PD,Zhang Y.The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease.Blood. 2013;122:4119-28
7. Kleer CG,Cao Q,Varambally S,Shen R,Ota I,Tomlins SA,Ghosh D,Sewalt RG,Otte AP,Hayes DF,Sabel MS,Livant D,Weiss SJ,Rubin MA,Chinnaiyan AM.EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.Proc Natl Acad Sci USA. 2003;100:11606-11
8. Varambally S,Dhanasekaran SM,Zhou M,Barrette TR,Kumar-Sinha C,Sanda MG,Ghosh D,Pienta KJ,Sewalt RG,Otte AP,Rubin MA,Chinnaiyan AM.The polycomb group protein EZH2 is involved in progression of prostate cancer.Nature. 2002;419:624-9
9. Ougolkov AV,Bilim VN,Billadeau DD.Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.Clin Cancer Res. 2008;14:6790-6
10. Wagener N,Holland D,Bulkescher J,Crnković-Mertens I,Hoppe-Seyler K,Zentgraf H,Pritsch M,Buse S,Pfitzenmaier J,Haferkamp A,Hohenfellner M,Hoppe-Seyler F.The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells.Int J Cancer. 2008;123:1545-50
11. Raman JD,Mongan NP,Tickoo SK,Boorjian SA,Scherr DS,Gudas LJ.Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.Clin Cancer Res. 2005;11:8570-6
12. Watanabe H,Soejima K,Yasuda H,Kawada I,Nakachi I,Yoda S,Naoki K,Ishizaka A.Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells.Cancer Cell Int. 2008;8:15-15
13. Tan J,Yang X,Zhuang L,Jiang X,Chen W,Lee PL,Karuturi RK,Tan PB,Liu ET,Yu Q.Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.Genes Dev. 2007;21:1050-63
14. Lu C,Han HD,Mangala LS,Ali-Fehmi R,Newton CS,Ozbun L,Armaiz-Pena GN,Hu W,Stone RL,Munkarah A,Ravoori MK,Shahzad MM,Lee JW,Mora E,Langley RR,Carroll AR,Matsuo K,Spannuth WA,Schmandt R,Jennings NB,Goodman BW,Jaffe RB,Nick AM,Kim HS,Guven EO,Chen YH,Li LY,Hsu MC,Coleman RL,Calin GA,Denkbas EB,Lim JY,Lee JS,Kundra V,Birrer MJ,Hung MC,Lopez-Berestein G,Sood AK.Regulation of tumor angiogenesis by EZH2.Cancer Cell. 2010;18:185-97
15. Fussbroich B,Wagener N,Macher-Goeppinger S,Benner A,Fälth M,Sültmann H,Holzer A,Hoppe-Seyler K,Hoppe-Seyler F.EZH2 depletion blocks the proliferation of colon cancer cells.PLoS One. 2011;6:e21651-e21651
16. Rao ZY,Cai MY,Yang GF,He LR,Mai SJ,Hua WF,Liao YJ,Deng HX,Chen YC,Guan XY,Zeng YX,Kung HF,Xie D.EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.Carcinogenesis. 2010;31:1576-83
17. Min J,Zaslavsky A,Fedele G,McLaughlin SK,Reczek EE,De Raedt T,Guney I,Strochlic DE,Macconaill LE,Beroukhim R,Bronson RT,Ryeom S,Hahn WC,Loda M,Cichowski K.An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB.Nat Med. 2010;16:286-94
18. Taniguchi H,Jacinto FV,Villanueva A,Fernandez AF,Yamamoto H,Carmona FJ,Puertas S,Marquez VE,Shinomura Y,Imai K,Esteller M.Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer.Oncogene. 2012;31:1988-94
19. Morin RD,Johnson NA,Severson TM,Mungall AJ,An J,Goya R,Paul JE,Boyle M,Woolcock BW,Kuchenbauer F,Yap D,Humphries RK,Griffith OL,Shah S,Zhu H,Kimbara M,Shashkin P,Charlot JF,Tcherpakov M,Corbett R,Tam A,Varhol R,Smailus D,Moksa M,Zhao Y,Delaney A,Qian H,Birol I,Schein J,Moore R,Holt R,Horsman DE,Connors JM,Jones S,Aparicio S,Hirst M,Gascoyne RD,Marra MA.Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.Nat Genet. 2010;42:181-5
20. Kodach LL,Jacobs RJ,Heijmans J,van Noesel CJ,Langers AM,Verspaget HW,Hommes DW,Offerhaus GJ,van den Brink GR,Hardwick JC.The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.Carcinogenesis. 2010;31:1567-75
21. He S, Zhou H, Zhu X, Hu S, Fei M, Wan D, Gu W, Yang X, Shi D, Zhou J, Zhou J, Zhu Z, Wang L, Li D, Zhang Y. Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance. Biomed Pharmacother 2014;68:507–13.
22. He SB, Zhao H, Fei M, Wu YG, Wang L, Zhu XG, Li DC. Expression of co-signaling molecules CD40-CD40L and their growth inhibitory effect on pancreatic cancer in vitro. Oncol Rep 2012;28:262–8.
23. Liu PF, Wu YY, Hu Y, Wang L, He SB, Zhu YB, Zhu XG. PAUF silencing by RNA interference inhibit the malignant phenotypes in human colorectal cancer cell. Oncol Rep 2013;30:213–20.
24. He S, Yuan Y, Wang L, Yu M, Zhu Y, Zhu X. Effects of cyclin-dependent kinase 8 specific siRNA on the proliferation and apoptosis of colon cancer cells. J Exp Clin Cancer Res 2011;30:109.
25. Zheng J, Li Y, Yang J, Liu Q, Shi M, Zhang R, Shi H, Ren Q, Ma J, Guo H, Tao Y, Xue Y, Jiang N, Yao L, Liu W. NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression. BMC Cancer 2011;11:1–9.
26. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008;647:21–9.
27. Arakawa T, Masaki T, Hirai T, Doi S, Kuratsune M, Arihiro K, Kohno N, Yorioka N. Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis. Nephrol Dial Transplant 2008;23:3418–26.
28. Yamada A, Fujii S, Daiko H, Nishimura M, Chiba T, Ochiai A. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Int J Oncol 2011;345–53.
29. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-b-catenin signaling. Cancer Cell 2011;19:86–100.
30. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011;17:2613–18.
31. Simon C, Chagraoui J, Krosl J, Gendron P, Wilhelm B, Lemieux S, Boucher G, Chagnon P, Drouin S, Lambert R, Rondeau C, Bilodeau A, Lavallée S, Sauvageau M, Hébert J, Sauvageau G. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev 2012;26:651–6.
32. Hock H. A complex Polycomb issue: the two faces of EZH2 in cancer. Genes Dev 2012;26:751–5.
33. Kelekar A, Thompson CB. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 1998;8:324–30.
34. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR. International Vidaza High-Risk MDS, Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–32.
35. Ghadjar P, Coupland SE, Na IK, Noutsias M, Letsch A, Stroux A, Bauer S, Buhr HJ, Thiel E, Scheibenbogen C, Keilholz U. Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol 2006;24:1910–6.
36. Chiba T, Suzuki E, NegishiM, Saraya A,Miyagi S, Konuma T, Tanaka S, Tada M, Kanai F, Imazeki F, Iwama A, Yokosuka O. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 2012;130:2557–67.
37. Tan J, Yang X, Zhuang L, Jiang X, ChenW, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007;21:1050–63.
38. Lotze MT, Maranchie J, Appleman L. Inhibiting antophagy: a novel approach for the treatment of renal cell cancinoma. Cancer 2013;341–7.
39. Zheng HY, Zhang XY, Wang XF, Sun BC. Autophagy enhances the aggressiveness of human colorectal cancer cells and their ability to adapt to apptotic stimulus. Cacer Biol Med 2012;9:105–10.
40. Gu W, Wan DW, Qian QY, Yi B, Gu YL, He ZL, Wang L, He SB. Ambra1 is an essential regulator of autophagy and apoptosis in SW620 cells: Prosurvival role of Ambra1. Plos One 2014;9:e90151.
41. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322:1695–9.
42. Wan DW, He SB, Xie BH, Xu GH, Gu W, Shen CL, Hu Y, Wang Xinsheng, Zhi QM, Wang L. Aberrant expression of miR-199a-3p and its clinical significance in colorectal cancers. Med Oncol 2013;30:378.
43. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF, Li XP. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011;71:225–33.